Dr. Jun Liu is a visionary executive and accomplished leader in the global biopharmaceutical industry with extensive experience bridging Western and Chinese pharmaceutical markets. He currently serves as CEO and Executive Board Director of BioDlink, where he provides strategic leadership and operational direction for the company's innovative drug development initiatives. His distinguished career began at Applied Biosystems, now part of the Danaher Group, where he engaged in proteomics research and provided cutting-edge technological solutions for prominent industry clients including Genentech and UCSF. He subsequently advanced his expertise at Bayer Healthcare in Berkeley, receiving comprehensive training in biological drug development, process optimization, and large-scale manufacturing at Bayer's largest biologics manufacturing facility, which employed over 1,600 specialists and provided him with deep knowledge of Good Manufacturing Practices and pharmaceutical production complexities.
Dr. Liu's strategic focus on antibody drug conjugates (ADCs) has established BioDlink as a first-tier ADC developer with proprietary pipeline assets in China. Beginning ADC development as early as 2013, well before the current industry surge, he pioneered the establishment of critical infrastructure including specialized conjugation laboratories, advanced drug product lines, comprehensive analytical capabilities, and robust antibody production facilities. This foresight and technical accumulation has enabled BioDlink to differentiate itself in the competitive biopharmaceutical landscape by pursuing high technical barrier areas with substantial long-term potential rather than crowded therapeutic spaces. His leadership in ADC development has significantly contributed to advancing targeted cancer therapies through precise drug delivery mechanisms that minimize systemic toxicity while maximizing therapeutic efficacy for patients.
As a trailblazer in establishing biological contract research and manufacturing services in China, Dr. Liu has played a pivotal role in the rapid growth of the country's biopharmaceutical sector since his return in 2010. His efforts contributed to the development of what became the largest biologic CRO/CDMO in the Shanghai region, initially focusing on small molecules before strategically expanding into large-molecule therapeutics. Under his leadership as CEO since joining BioDlink's management team in 2016, the company has undergone a significant strategic transformation to become a specialized biopharmaceutical CDMO with particular expertise in complex modalities. Dr. Liu continues to drive innovation in the ADC space, positioning BioDlink at the forefront of next-generation targeted therapies while fostering international collaborations that bridge technological and geographical divides in the global biopharmaceutical ecosystem.
